Zacks Investment Research upgraded shares of Chromedx Corp (MNLIF) from N/A to NEUTRAL on October 14, 2014, with a target price of $0.25.
ChroMedX Corp is in the process of commercializing medical devices with disruptive technology in the In-Vitro Diagnostics (IVD) and Point-of-Care (POC) markets. The company has developed a hand-held unit that is a combination of a blood-gas analyzer and a co-oximeter. ChroMedX's other device offers a novel method of rapid sample preparation for measurement of free therapeutic drugs and hormones, using the existing immunoassays.In the following pages we describe the technology in detail. Currently we are waiting on the products to hit the market and that keeps us at a Hold rating.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Chromedx Corp (MNLIF),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment